mRNA CAR-T cells targeting protein kinase Met (c-Met) are in clinical development for the treatment of breast cancer and melanoma (NCT01837602, NCT03060356) [161], and B-cell maturation antigen (BCMA)-specific mRNA CAR-T cells are being developed as a treatment option for multiple myeloma (NCT03448978) [156]. The gene discussed is TNFRSF17; the disease is breast carcinoma.